J.P. Morgan Life Sciences Private Capital Hires Joseph Sillett to Invest in Healthcare Transformation

Sillett joins as co-managing partner from Vivo Capital

new york, July 11, 2024 /PRNewswire/ — JPMorgan Private Capitalthe venture and growth equity investment team within J.P. Morgan Asset Management Alternatives, today announced it has entered its next phase of growth with the hiring of industry veteran Joseph Sillett as its new Managing Partner alongside Anya Sheth and Gaurav Gupta, MD, MSE, reporting to Dr. Steven Squint, Ph.D. The expanded team will seek Series B investments through pre-IPO healthcare companies with a focus on the biotechnology, medical devices, health technology and services, and diagnostics and tools subsectors.

“I am excited to join J.P. Morgan Life Sciences Private Capital’s globally respected team.” Joseph Sillett, Managing Partner, JPMorgan Life Sciences Private Capital“As part of a world-class investment team, we look forward to leveraging J.P. Morgan’s existing presence in the healthcare space, which we believe will give us a significant sourcing advantage as we identify innovative, transformative healthcare companies.”

Back BostonMr. Sillett has over 25 years of experience investing in the private healthcare sector and most recently served as Managing Director at Vivo Capital and prior to that role was co-founder of Scion Medical Technologies.

The expanded platform seeks to fund opportunities that aim to improve disease treatment and patient outcomes while reducing costs through several key initiatives, including supporting innovative therapeutic approaches, leveraging cutting-edge technology and increasing computational power through artificial intelligence to develop more effective treatments, improving diagnostic tools for early detection and prevention of diseases, and providing healthcare solutions to patients in a more cost-effective manner.

“As advances in biotechnology and artificial intelligence continue to transform the healthcare industry, our expanded team should enable us to capitalize on these changes and remain the preferred partner for companies looking to introduce innovative ways to treat, identify and prevent disease,” he said. Anya Schiess, Managing Partner, JPMorgan Life Sciences Private Capital.

biography

Joseph Sillett is a Co-Managing Partner of Life Sciences Private Capital (“LSPC”) within J.P. Morgan Private Capital, a division of J.P. Morgan Asset Management’s J.P. Morgan Global Alternatives. Joseph joined the firm in 2024 from Vivo Capital. During his time at Vivo, Joseph focused on sourcing investments, executing transactions and serving on the boards of growth and private equity companies. During his time at the firm, he sourced and served on the boards of over 10 companies. In addition to his investments and board responsibilities, Joseph also held active operating roles in several portfolio companies. Prior to joining Vivo, Joseph developed the business plan and was a co-founder of Scion Medical Technologies. The company completed six acquisitions to build a global commercial medical device portfolio focused on interventional oncology. Scion was ultimately sold to NYSE-listed Varian Medial, now a division of Siemens. Prior to becoming an entrepreneur and investor, Joseph was an investment banker at Cowen & Company and Bank of America Securities, focusing on healthcare M&A and capital raising. Joseph holds a BA from Duke University and an MBA from the University of New Hampshire Haas School of Business. California in Berkeley.

About J.P. Morgan Private Capital

JP Morgan Private Capital is focused on venture and growth investing, providing customized financing solutions to private companies across the capital structure. The platform’s solutions span the consumer, technology and life sciences sectors.

J.P. Morgan Private Capital is a division of J.P. Morgan Global Alternatives, the alternative investment division of J.P. Morgan Asset Management. With more than 60 years of experience managing alternative investments, $214 billion With $20 million in assets under management and over 800 professionals (as of March 31, 2024), its strategies cover all alternative sectors, including real estate, private equity, private credit, liquid alternatives, infrastructure, transportation, hedge funds and forestry. Americas, Europe and AsiaOur independent alternative investment team combines cutting-edge expertise with J.P. Morgan’s resources, infrastructure and global network to achieve each client’s specific objectives. For more information, please visit jpmorgan.com/am.

About J.P. Morgan Asset Management

JPMorgan Asset Management, assets under management $3.2 trillion (as of March 31, 2024) is a global leader in investment management. J.P. Morgan Asset Management’s clients include institutions, retail investors and high net worth individuals in every major market around the world. J.P. Morgan Asset Management provides global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information, please visit www.jpmorganassetmanagement.com. J.P. Morgan Asset Management is the marketing name for the asset management businesses of JPMorgan Chase & Co. and its affiliates worldwide.

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services company based in the United States. united states of america (“we“) operates worldwide. JPMorgan Chase $4.1 trillion Assets and $337 billion As of March 31, 2024, the company has stockholders’ equity of $100 billion. The company is a leader in investment banking, consumer and small business financial services, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the company serves millions of customers around the world. weand many of the world’s leading corporations, institutional investors and government agencies around the world. Information about JPMorgan Chase & Co. can be found at www.jpmorganchase.com.

The past investment and operating experience of JPMorgan Life Sciences team members is provided solely to indicate the nature of their professional experience with respect to the types of investments and transactions JPM seeks to pursue and is not indicative of JPM’s future results, should not be understood as JPM’s “performance” information, and should not be relied upon in connection with any investment or other related decisions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/jp-morgan-life-sciences-private-capital-hires-joseph-siletto-to-target-investments-in-healthcare-transformation-302194781.html

Source: JPMorgan Asset Management